AVANOS MEDICAL INC

Avanos Medical’s merger delivers $25/share cash, ending its NYSE listing while keeping FDA‑cleared infection‑control tech for A‑AV Holdco I’s future growth.

Avanos Medical CFO’s April 22 sale: a tax‑withholding move, not a warning. Learn how AIP’s pending acquisition could boost the medical‑device stock’s future.

Avanos Medical’s CEO sells shares amid a $1.3 billion AIP acquisition: insider moves, valuation impacts, and future infection‑prevention & pain‑management growth prospects.

Avanos Medical insider buys 2,211 restricted shares, signaling strong confidence in the company’s electrosurgical product pipeline and long‑term upside.

Avanos Medical insider sales show routine tax‑withholding, not strategic divestment—while its spine‑device pipeline delivers strong clinical outcomes and regulatory momentum.